The premium and deal structure suggest the stock should trade near the $3.16 cash consideration (adjusted for time value and deal risk) pending shareholder vote. CVR value is highly contingent on commercial milestones for NEXLETOL/NEXLIZET and ENBUMYST. Monitor proxy solicitation results and regulatory HSR clearance. Spread widening could present an arbitrage entry, but CVR complexity and uncertainty around milestone achievement add risk.
Price Chart
Executive Summary
Esperion Therapeutics has filed a preliminary proxy statement (PREM14A) for its acquisition by an affiliate of ArchiMed SAS. Stockholders will receive $3.16 per share in cash plus one contingent value right (CVR) per share, with potential milestone payments of up to $100M in aggregate tied to U.S. net sales milestones. The Board unanimously recommends approval. Total transaction value is approximately $1.08 billion including debt financing. The special meeting to vote on the merger is expected in Q3 2026.
Key Financial Metrics
Key Facts
- Stockholders to receive $3.16 per share in cash plus one CVR per share
- CVR provides potential additional payments: up to $40M tied to bempedoic acid products' 2027 U.S. net sales exceeding $300M-$350M, and up to $60M tied to ENBUMYST U.S. net sales of $160M+ in any single calendar year through 2030
- Total financing of approximately $1.08 billion: $706.1M equity commitment and $550M debt commitment ($400M funded at close)
- Cash consideration represents ~58% premium to $2.00 closing price on April 30, 2026
- Board unanimously recommends FOR the merger; Centerview Partners rendered fairness opinion
- Merger expected to close in Q3 2026, subject to stockholder vote, HSR, and German antitrust approval
Financial Impact
Clear premium to unaffected price. $3.16/share cash plus CVR with up to $0.32/share at maximum milestone payout, or an illustrative risk-adjusted NPV of $0.15/share.
Risk Factors
- Failure to obtain stockholder approval for merger
- Regulatory delays or failure to obtain HSR/German antitrust clearance
- Potential for superior proposal triggering termination fee ($34.2M)
- CVR milestones may not be achieved, leaving only $3.16/share
- Post-merger debt burden (~$400M at close) on operating performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREM14A Filing (Primary) | 0001104659-26-068371 |
| Document: tm2615754d1_ex-filingfees.htm | 0001104659-26-068371 |
| Document: 0001104659-26-068371-index-headers.html | 0001104659-26-068371 |
| Document: 0001104659-26-068371-index.html | 0001104659-26-068371 |
| Document: 0001104659-26-068371.txt | 0001104659-26-068371 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access